Trial Profile
Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Sep 2012
Price :
$35
*
At a glance
- Drugs ARRY 403 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 05 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Aug 2009 Primary and secondary endpoints have been met, according to an Array biopharma media release.
- 11 Aug 2009 Positive top-line data announced in an Array Biopharma media release. Combined results of the single and multiple ascending-dose ARRY 403 studies will be reported at an upcoming scientific meeting during the first half of 2010.